Litmys Debuts RAMPx to Identify and Address Commercial Risk in Life Sciences Product Development
New 12-factor scoring model aims to identify and mitigate commercial underperformance early
Santa Fe, New Mexico — April 7th, 2026 — Litmys, a life sciences commercial strategy firm, today announced the launch of RAMPx (Realistic Assessment of Market Potential), a 12-factor scoring model designed to help life sciences companies identify and mitigate commercial risk earlier in the product development process, especially since about 50% of new products achieve clinical and regulatory success but underperform financially in the market.
Despite billions invested in clinical development, many new therapies underperform in the market because critical commercial drivers that drive new product adoption in today’s commercial environment were not fully considered early enough. Clinical trial designs are typically optimized for regulatory approval, yet the trial design and clinical endpoint decisions made at this stage often determine a product’s ultimate commercial trajectory. Clinical endpoints define the product label, the label shapes the message, and the message ultimately establishes the ceiling for adoption and revenue. By embedding commercial insight earlier in the development process, the model aims to improve return on clinical investment and reduce the risk of post-launch underperformance.
“The industry has too long separated clinical success from commercial success and that’s the problem,” said Harris Kaplan, Litmys Managing Partner at Litmys. “By the time most companies begin to rigorously assess commercial potential, the most important decisions have already been made. RAMPx is designed to change that.”
RAMPx introduces a standardized, data-driven framework that evaluates products in development across a comprehensive set of demand drivers, including relative clinical differentiation, ease with which the new product can be incorporated into a physician practice or patient’s lifestyle, and willingness of someone to be an early adopter. The RAMPx model output is a clear, FICO-like score that translates complex commercial dynamics into a simple, comparable metric. This allows CEOs, investors, and business development teams to more effectively assess asset value, prioritize development decisions, and communicate opportunity across portfolios.
RAMPx creates a common language for assessing commercial potential. It allows organizations to move beyond intuition and bring real future customer input to a company’s thinking. As the model uses consistent metrics, it cuts through internal biases, and fragmented or non-existent analyses to a more disciplined, repeatable approach for evaluating and optimizing new products or a company’s pipeline.
Designed to be both rigorous and practical, RAMPx can be accessibly implemented by companies at all stages of development—from emerging biotech firms to large pharmaceutical organizations managing diverse portfolios.
The launch of RAMPx reflects Litmys’ broader mission to help life sciences companies make better, more integrated decisions that will result in more products being meaningfully differentiated and improve the financial returns from products approved and launched.
# # #
About Litmys
Litmys is a life sciences commercial strategy firm focused on helping life sciences companies maximize the commercial potential of their products. By integrating clinical, market, and behavioral insights, Litmys enables more informed decision-making across development and commercialization. The firm’s proprietary models and frameworks are designed to bring greater rigor, clarity, and alignment to complex strategic choices. Litmys is headquartered in Santa Fe, New Mexico, with an additional office in Minneapolis, Minnesota. Learn more at www.litmys.com